Programmed death-ligand 1 (PD-L1) is an important biomarker increasingly used as a predictive marker in breast cancer immunotherapy. Immunohistochemical quantification is the current standard assessme
Table S1. Autoencoder architecture and parameter evaluation. New encoded features were used to compute tissue of origin. A better separation between the first top site and the second top site indicate
